サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1247468

ライフサイエンス機器の世界市場-2023-2030

Global Life Science Instrumentation Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ライフサイエンス機器の世界市場-2023-2030
出版日: 2023年03月28日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

ライフサイエンス機器の世界市場は、2022年に560億米ドルに達し、2030年には最大1,070億米ドルに達すると予測されます。同市場は予測期間中（2023年～2030年）、CAGR7.9%で成長してゆきます。

歩留まりを最大化し、プロセス制御を維持するために、ライフサイエンス、特にバイオテクノロジー、医薬品、医療機器には、信頼性が高く正確な計測機器が必要です。製造工場におけるプロセスの調整や監視、製品の品質評価に使用される機器は、ライフサイエンス機器として知られています。一般的には、物理学、工学、生物科学の融合と捉えられています。バイオテクノロジーの領域では、分子生物学や生物を科学的に調べるために必要不可欠なツールです。

市場力学

医薬品の研究開発に費やす投資額が増加していること。

バイオテクノロジーや医薬品などの企業では、研究開発への投資が盛んに行われています。その背景には、迅速な医薬品開発への欲求の高まりと、珍しい病気の治療のための新規薬理化合物の商業化があります。

世の中の病気の負担と研究開発費の高騰が、ライフサイエンス機器の需要を本質的に押し上げているのです。また、製薬業界の創薬開発への投資拡大により、医薬品バリデーション用のライフサイエンスツールの需要も増加すると思われます。ライフサイエンス研究に対する官民の投資の拡大や分析機器技術の進歩が、ライフサイエンス機器・化学品の市場を牽引しています。

例えば、2022年10月に英国議会が発表した記事によると、英国は2022年に研究開発に総額375億ユーロを支出しました。また、OECDのデータによると、2021年のGDPに占める医薬品の割合は、ブルガリアが約33.0％と最も多く費やしています。したがって、研究開発活動に対する医薬品支出の増加により、市場の拡大が期待されます。

ある種のがんの製品は、ライフサイエンス機器に基づく医薬品を使用して効果的に治療することができます。これにより、発展途上国や低開発国のヘルスケアコストを下げることができます。ライフサイエンス機器の市場は、世界的にがん患者が増加するにつれて拡大すると思われます。

機器のコストが高いことが、市場成長の妨げになると思われます。

ライフサイエンス機器市場の開拓は、機器の高コスト、有能な労働力の不足、qPCRおよびdPCR手順の技術的限界、高性能顕微鏡の高コストによって制約を受けると思われます。一方、新興諸国における研究インフラの不在や価格圧力により、市場の拡大が脅かされる可能性があります。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲について

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 製品別スニペット
  • 技術別スニペット
  • 地域別スニペット

第4章 ダイナミックス

  • インパクトのあるファクター
    • 促進要因
      • ライフサイエンス研究のための官民ファンドの拡大
      • 慢性疾患の普及が進んでいる
    • 抑制要因
      • 機器の高コストが市場成長の妨げになります
    • 機会
    • 影響度分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格アナリシス
  • レギュラトリー・アナリシス

第6章 COVID-19の分析

  • COVID-19の解析について
    • COVID-19シナリオ前
    • 現在のCOVID-19シナリオ
    • ポストCOVID-19または未来シナリオ
  • COVIDの中での価格ダイナミクス-19
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • 結論

第7章 テクノロジー別

  • スペクトロスコピー
  • ポリメラーゼ連鎖反応（PCR）
  • クロマトグラフィー
  • フローサイトメトリー
  • 電気泳動
  • 遠心分離機
  • その他

第8章 アプリケーション別

  • 調査
  • 臨床・診断

第9章：By End suer

  • 製薬会社・バイオテクノロジー企業
  • アグリ・食品産業
  • 病院・診断所

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢について

  • 競合シナリオ
  • 市況分析・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Bio-Rad Laboratories Inc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な展開
  • Agilent Technologies Inc
  • PerkinElmer, Inc
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • JEOL Ltd
  • Shimadzu Corporation
  • Becton, Dickinson & Company
  • HORIBA, Ltd.,
  • Bruker Corporation

第13章 付録

目次
Product Code: MD1529

Market Overview

The global Life Science Instrumentation market reached US$ 56,000 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 107,000 million by 2030. The market is growing at a CAGR of 7.9% during the forecast period (2023-2030).

To maximize yields and maintain process control, life sciences, particularly biotechnology, pharmaceuticals, and medical devices, need dependable and accurate instrumentation. The equipment used to regulate and monitor the process in manufacturing plants, as well as to assess the quality of the products, is known as life science instrumentation. It is generally seen as the fusion of physics, engineering, and biological sciences. In the realm of biotechnology, these tools are essential for the scientific examination of molecular biology and living things.

Market Dynamics

The increasing investments spending on pharmaceutical research and development.

In companies like biotechnology and pharmaceuticals, there is a large investment in R&D. The increased desire for quick medication development and the commercialization of novel pharmacological compounds for the treatment of uncommon illnesses are to blame for this.

The burden of illness in the world and rising R&D costs are what essentially drive the demand for life science devices. Also, there will likely be a rise in demand for life science tools for drug validation due to the pharmaceutical industry's growing investment in drug discovery and development. Growing public-private investments in life science research as well as advancements in analytical equipment technology are driving the market for life science instruments and chemicals.

For instance, according to an article released by the UK Parliament in October 2022, the UK spent a total of EUR 37.5 billion on research and development in 2022. Also, according to OECD data, Bulgaria spent the most on pharmaceuticals as a proportion of GDP in 2021, at about 33.0%. Hence, it is anticipated that market expansion will be aided by rising pharmaceutical spending on R&D activities.

A certain Product of cancer can be effectively treated using drugs based on Life Science Instrumentation. This lowers the cost of healthcare for developing and underdeveloped nations. The Life Science Instrumentation market should grow as cancer cases rise globally.

The high cost of instruments will hamper the growth of the market.

The development of the life science instrumentation market will be constrained by the high cost of instruments, a shortage of competent labor, technological limitations on qPCR and dPCR procedures, and the high cost of sophisticated microscopes. On the other hand, the expansion of the market can be threatened by the absence of research infrastructure in developing countries and price pressure.

Segment Analysis

The global Life Science Instrumentationmarket is segmented based on technology, application, end user and region.

The technology segment is expected to grow at the fastest CAGR during the forecast period(2023-2030)

Based on technology, the global Life Science Instrumentation market is segmented into Spectroscopy, Polymerase Chain Reaction (PCR), Chromatography, Flow Cytometry, Electrophoresis, Centrifuges and Others. Among these, The DNA polymerase's ability to build new DNA strands that are supporting to the provide template strand forms the basis of PCR. DNA polymerase requires a primer on which it may add the first nucleotide since it can only add a nucleotide onto an already-existing 3'-OH group.

This prerequisite allows the researcher to identify a particular area of the template sequence that they want to amplify. The specified sequence will accumulate in billions of copies at the end of the PCR cycle (amplicons). The segment is driven by the increasing prevalence of chronic and infectious diseases as well as the rising demand for precise and expedient disease diagnosis methods. Also, the segment is being driven by the development of technologically improved products and an increase in healthcare expenditure.

For instance, on January 2022, during Arab Health 2022, Irish diagnostics company HiberGene Diagnostics will introduce its PCR Adapt COVID-19 test. Ireland's leading manufacturer, developer, and producer of Molecular Diagnostics products is HiberGene, which holds an ISO certification. HiberGene's elite team created the ground-breaking PCR Adapt COVID-19 test as part of a plan to diversify the company's line of products.

On Feburaury 2023, To further advance healthcare and innovation in the Kingdom of Saudi Arabia, Tamer Healthcare, an integrated healthcare and wellness company with more than 100 years of established business in the Kingdom of Saudi Arabia, and Digital Diagnostics, the company behind IDx-DR, the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy, have announced a strategic partnership.

Geographical Penetration

The expansion of the industry is being facilitated by an increase in R&D efforts.

North America has established itself as the dominant market participant in the Life Science Instrumentations market. Life science and chemical instrumentation technology are used extensively in the pharmaceutical and biotechnology sectors in North America. Chemical instrumentation has shown to be an effective technological tool for a number of uses, including final production testing, pharmaceutical applications, environmental monitoring, and food testing.

Also, the expansion of the industry is being facilitated by an increase in R&D efforts. For instance, according to a 2021 update from the University of North Dakota, the National Institutes of Health (NIH) will continue to support the project through Phase II, according to the UND Center of Biomedical Research Excellence (CoBRE) in Host-Pathogen Interactions (HPI). The renewal of USD 10.7 million aims to further knowledge of how the body reacts to bacterial, viral, and parasitic infections that lead to acute and long-term inflammatory disorders. Thus, it is anticipated that increased R&D investment for various life sciences-related research will spur market expansion over the projection period.

Competitive Landscape

The major global players include Bio-Rad Laboratories Inc, Agilent Technologies Inc, PerkinElmer, Inc, F. Hoffmann-La Roche Ltd., Danaher Corporation, JEOL Ltd, Shimadzu Corporation, Becton, Dickinson & Company, HORIBA, Ltd. and Bruker Corporation.

COVID-19 Impact Analysis

By Technology

  • Spectroscopy
  • Polymerase Chain Reaction (PCR)
  • Chromatography
  • Flow Cytometry
  • Electrophoresis
  • Centrifuges
  • Others

By Application

  • Research
  • Clinical and Diagnostic

By End user

  • Pharma-Biotech
  • Agri and Food Industry
  • Hospitals & Diagnostic Labs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2022, A novel Fourier transform infrared spectrophotometer called the IRXross has been made available by Shimadzu Company. The sensitivity and resolution of this model are around twice as high as those of the IRAffinity-1S, its forerunner. The addition of the IR Pilot, an analytical help application that even novice users may use, has increased usability.
  • In October, 2021, SFDA has now approved a COVID-19 RT-PCR test that was developed by KAUST and first utilized in the United Kingdom. The service was launched at KAUST Health by KAUST company Noor DX. Noor DX offers a broad range of processing equipment using biotech diagnostics and is located in the Core Laboratories at KAUST. In the fight against COVID-19, this novel RT-PCR has the potential to be a game-changer, not just for Saudi Arabia but also for other nations looking for affordable, easily implemented diagnostics.
  • On August 2022, an agreement to acquire all of Curiosity Diagnostics' outstanding shares was announced by Bio-Rad Laboratories, Inc., a pioneer in life science research and clinical diagnostic products. For the molecular diagnostics business, Curiosity Diagnostics, a late-stage, pre-commercial platform company, is developing a sample-to-answer PCR system.

Why Purchase the Report?

  • To visualize the global Life Science Instrumentation- marketsegmentation based on Product, Technology, and region,as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerousdata points of Life Science Instrumentationmarket-level with allsegments.
  • PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key productsof all the major players.

The global Life Science Instrumentationmarketreport would provide approximately 53 tables,54figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Expanding public-private funding for life science research
      • 4.1.1.2. Increasing prevalence of chronic illnesses.
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. The high cost of instruments will hamper the growth of the market.
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. XX
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. PostCOVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. ByTechnology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Spectroscopy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Polymerase Chain Reaction (PCR)
  • 7.4. Chromatography
  • 7.5. Flow Cytometry
  • 7.6. Electrophoresis
  • 7.7. Centrifuges
  • 7.8. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByTechnology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Research *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical and Diagnostic

9. By End suer

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByTechnology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Pharmaceutical and Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Agri and Food Industry
  • 9.4. Hospitals & Diagnostic Labs

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Russia
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bio-Rad Laboratories Inc
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Agilent Technologies Inc
  • 12.3. PerkinElmer, Inc
  • 12.4. F. Hoffmann-La Roche Ltd.
  • 12.5. Danaher Corporation
  • 12.6. JEOL Ltd
  • 12.7. Shimadzu Corporation
  • 12.8. Becton, Dickinson & Company
  • 12.9. HORIBA, Ltd.,
  • 12.10. Bruker Corporation

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us